References
- Kocabas CN, Civelek E, Sackesen C, et al. Burden of rhinitis in children with asthma. Pediatr Pulmonol. 2005 Sep;40(3):235–240.
- Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004 Oct 15;170(8):836–844.
- Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012 Mar;129(3):717–725 e5.
- Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007 Aug;62(8):943–948.
- Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014 Sep;134(3):568–575 e7.
- Mosbech H, Canonica GW, Backer V, et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann Allergy Asthma Immunol. 2015 Feb;114(2):134–140.
- Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2016 Feb;137(2):444–451 e8.
- Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016 Apr 26;315(16):1715–1725.
- Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica de Acarizax®; [cited 2020 Mayo]. Available from: https://cima.aemps.es/cima/dochtml/ft/81213/FT_81213.html
- Agache I, Lau S, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: house dust mite-driven allergic asthma. Allergy. 2019 May;74(5):855–873.
- Globat Initiative for Asthma (GINA). Global strategy for asthma management and prevention; 2020 [cited 2020 mayo]. Available from: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf
- Guía Española para el Manejo del Asma (GEMA) Versión 5.0. [cited 2020 mayo]. Available from: https://www.gemasma.com/
- Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000 Oct;32(4):1008–1015.
- Kim JA, Lee YM, Yi KI, et al. Comparative analysis of sublingual immunotherapy medicines for adherence and clinical outcomes. Eur Arch Otorhinolaryngol. 2020 Jan;277(1):135–140.
- Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol. 2015 Jun;135(6):1494–501 e6.